Findings seen among children and adolescents with type 1 diabetes and nonoptimal control with traditional treatment
THURSDAY, Dec. 12, 2024 (HealthDay News) — Initiation of an automated insulin delivery (AID) system improves glycemic control in children and adolescents with type 1 diabetes (T1D), according to a study published in the January issue of Diabetes, Obesity and Metabolism.
Maaria Kiilavuori, M.D., from the University of Helsinki, and colleagues investigated the influence of an AID system on glycemic control in children and adolescents with T1D who do not reach optimal glycemic control with traditional treatment options (hemoglobin A1C >53 mmol/mol/7.0 percent). The analysis included 79 patients (aged 7 to 16 years) with T1D.
The researchers found that after the initiation of an AID system, glycemic control improved and the effect persisted throughout the study period. Between zero and three months, time in tight range and time in range increased (mean, 11.7 and 18.1 percent, respectively). During the same follow-up period, hemoglobin A1c and mean sensor glucose values decreased significantly. These effects were sustained at 12 and 24 months.
“Glycemic control in patients not reaching treatment goals improved significantly after the initiation of the AID system, and the favorable effect lasted throughout the follow-up,” the authors write. “AID treatment could be an option for also those pediatric patients with T1D who do not have good skills in diabetes management.”
Several authors disclosed ties to the pharmaceutical and medical device industries.
Weight-Loss Surgery Produces Lasting Diabetes Remission
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets
Time-Restricted Eating May Help Patients With Type 1 Diabetes
GLP-1 Receptor Agonist Use Does Not Increase Insulin Discontinuation With Type 2 Diabetes
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes